Loading organizations...
Loading organizations...
Moleculent is a technology company.
Moleculent has raised $26.0M across 1 funding round.
Moleculent has raised $26.0M in total across 1 funding round.
Moleculent is adding a functional layer of biology to pave the way for unparalleled advancements in life science, focusing on cell-cell communication and its implications for diseases.
Moleculent has raised $26.0M in total across 1 funding round.
Moleculent's investors include ARCH Venture Partners, Eir Ventures.
Moleculent is a biotechnology company developing technology that maps cell-cell communication in human tissue to uncover insights into cellular functions and disease pathways.[1] This platform targets researchers and healthcare professionals tackling complex diseases like cancer and neurodegenerative disorders, addressing the challenge of understanding intricate biological interactions at a tissue level.[1] Founded in 2021 and headquartered in Solna, Sweden, Moleculent has raised $26M in a Series A round, signaling strong early growth momentum in the life sciences sector.[1]
Moleculent was founded in 2021 in Solna, Sweden, emerging as a life science innovator focused on a "functional layer of biology" within biotechnology.[1] While specific founder details are not publicly detailed in available sources, the company's rapid progression to a $26M Series A round—led by prominent investors ARCH Venture Partners and EIR Ventures—marks a pivotal early milestone, reflecting immediate traction in mapping cell-cell interactions for disease research.[1] This funding, secured about eight months prior to mid-2025, underscores investor confidence in its foundational technology amid rising demand for advanced biotech tools.[1]
Moleculent stands out in biotechnology through targeted innovations:
Moleculent rides the wave of spatial biology and multi-omics trends, where mapping cellular interactions at tissue resolution is transforming drug discovery and personalized medicine.[1] Its timing aligns with surging investments in biotech tools post-2021, fueled by advances in single-cell sequencing and AI-driven analysis, which amplify the need for platforms decoding disease microenvironments.[1] Market forces like aging populations driving neurodegenerative research and oncology breakthroughs favor Moleculent, as its tech influences the ecosystem by accelerating pathway identification for novel therapies.[1] In Sweden's robust life sciences hub, it contributes to Europe's push against U.S.-dominated biotech innovation.
Moleculent is poised for expansion with its $26M war chest, likely advancing platform validation through partnerships and pilot studies in cancer and neurodegeneration.[1] Trends like AI integration in spatial transcriptomics and regulatory tailwinds for precision medicine will shape its trajectory, potentially leading to Series B funding or commercial pilots by 2026.[1] Its influence may evolve from research tool to therapeutic discovery engine, amplifying impact in the biotech startup ecosystem as backers like ARCH Venture Partners scale similar pioneers. This positions Moleculent as a key player decoding biology's next frontier, building on its strong Series A momentum.[1]
Moleculent has raised $26.0M across 1 funding round. Most recently, it raised $26.0M Series A in June 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2024 | $26.0M Series A | ARCH Venture Partners, Eir Ventures |